Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: A cohort study

BMJ Open

Volumn 2, Issue 6, 2012, Pages

  Oliveira, Inés ^a,b   Andersen, Andreas ^a   Furtado, Alcino ^a   Medina, Candida ^c   Da Silva, David ^c   Da Silva, Zacarias J ^a,d   Aaby, Peter ^a,e   Laursen, Alex Lund ^f,g   Wejse, Christian ^f,g,h   Eugen Olsen, Jesper ^b  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Ministry of Health   (Guinea-Bissau)

^d National Public Health Laboratory   (Guinea-Bissau)

^e STATENS SERUM INSTITUT   (Denmark)

^f Department of Infectious Diseases ^*  (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; UROKINASE RECEPTOR;

ADULT; ARM CIRCUMFERENCE; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; GUINEA-BISSAU; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 84871084200     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001587     Document Type: Article

References (50)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29. (Pubitemid 34786200)
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;160:659-65. (Pubitemid 29149796)
3. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
4. World Health Organisation (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS) and United Nations Children Fund (UNICEF),GLOBAL HIV/AIDS RESPONSE-Epidemic update and health sector progress towards Universal Access- Progress Report 2011. Geneva, WHO, UNAIDS, UNICEF. 2011. http://www.unaids.org/ en/media/unaids/contentassets/documents/unaidspublication/ 2011/20111130-UA- Report-en.pdf (accessed 12 Jan 2011).
5. World Health Organization (WHO). New progress and guidance on HIV treatment: fact sheet. Geneva, 2010. http://www.who.int/hiv/vienna2010/en/index. html (accessed 12 Jan 2011).
6. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006;20:1163-9. (Pubitemid 43786105)
7. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009;23:2199-208.
8. Reus S, Portilla J, Gimeno A, et al. Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy. Enferm Infecc Microbiol Clin 2004;22:142-9. (Pubitemid 38541593)
9. Braun J, Plantier JC, Hellot MF, et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 2003;17:331-6. (Pubitemid 36223257)
10. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-17.
11. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008;371:1443-51. (Pubitemid 351635534)
12. van der Sande MA, Schim van der Loeff MF, Aveika AA, et al. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004;37:1288-94. (Pubitemid 39281511)
13. Castetbon K, Anglaret X, Toure S, et al. Prognostic value of cross-sectional anthropometric indices on short-term risk of mortality in human immunodeficiency virus-infected adults in Abidjan, Cote d'Ivoire. Am J Epidemiol 2001;154:75-84. (Pubitemid 32565689)
14. Maas JJ, Dukers N, Krol A, et al. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:254-9.
15. Lawn SD, Myer L, Bangani N, et al. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis 2007;7:41.
16. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007;12:929-35. (Pubitemid 47245826)
17. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005;19:2050-2. (Pubitemid 41669038)
18. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007;21:2483-91. (Pubitemid 350145180)
19. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards an universal access. Geneva: WHO, 2006.
20. Lindan CP, Allen S, Serufilira A, et al . Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 1992;116:320-8.
21. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157-72.
22. Jaffar S, Van der Loeff MS, Eugen-Olsen J, et al. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses 2005;21:560-4. (Pubitemid 40944318)
23. Hazenberg MD, Hamann D, Schuitemaker H, et al. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000;1:285-9.
24. Ostrowski SR, Katzenstein TL, Piironen T, et al. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:337-42. (Pubitemid 38332793)
25. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infections. Ann N Y Acad Sci 1988;546:164-74. (Pubitemid 19200622)
26. Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000;96:4091-5.
27. Ostrowski SR, Piironen T, Hoyer-Hansen G, et al. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23-31. (Pubitemid 40617015)
28. Oliveira I, Jensen-Fangel S, da Silva D, et al. Epidemic Stevens-Johnson syndrome in HIV patients in Guinea-Bissau: a side effect of the drug-supply policy? AIDS 2010;24:783-5.
29. UNDP. Human Development Report 2009. Overcoming barriers: Human mobility and development, New York, 2009.
30. United Nations Development Programme (UNDP). Human Development Report 2011.Sustainability and equity: a better future for all. http://hdr.undp.org/en/ media/HDR-2011-EN-Summary.pdf. 2011. (accessed 14 Jan 2011).
31. UNAIDS. Suivi de la Déclaration d'engagement sur le VIH/ sida. Guinea-Bissau. Rapport sur la période 2008-2009. Mars 2010. http://www.unaids.org/fr/dataanalysis/monitoringcountryprogress/ 2010progressreportssubmittedbycountries/file,57978,fr.pdf (accessed 27 Mar 2012).
32. Oliveira I, Andersen A, Rasmussen DN, et al. Running before walking: Experiences from the implementation of the HIV Programme in Guinea-Bissau. PhD thesis, University of Copenhagen, 2011.
33. WHO. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. http://www.who.int/hiv/pub/ prev-care/en/arvrevision2003en.pdf (accessed 14 Jan 2011), 2003.
34. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009;4:e5790.
35. Shetty PS, James WPT. Body mass index-a measure of chronic energy deficiency in adults. FAO Food Nutr Pap 1994;56:1-57.
36. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
37. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006;20:2355-60. (Pubitemid 44789538)
38. Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care 2012;16:R130.
39. Honge BL, Jespersen S, Oliveira I, et al. Abstract presentation. Hepatitis B prevalence and mortality among HIV-infected patients in Guinea-Bissau. 28th Annual NSCMID Conference; Reykjavik, 2011.
40. Honge BL. Research year report: Heaptitis prevalence and impact in a West Africa HIV cohort, Aarhus Universitet, 2012.
41. Gustafson P, Gomes VF, Vieira CS, et al. Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. Int J Epidemiol 2004;33:163-72. (Pubitemid 38500173)
42. Rabna P, Andersen A, Wejse C, et al. Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment. PLoS One 2012;7:e43933.
43. Zimmermann HW, Koch A, Seidler S, et al . Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 2012;32:500-9.
44. Ostrowski SR, Katzenstein TL, Pedersen M, et al. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand J Immunol 2006;63:478-86. (Pubitemid 43978863)
45. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents -November 2009 (electronic version). 2009.
46. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003;34:281-8. (Pubitemid 37377361)
47. Elise A, France AM, Louise WM, et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2005;40:498-500. (Pubitemid 41669187)
48. Laurent C, Meilo H, Guiard-Schmid JB, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 2005;41:108-11. (Pubitemid 40863752)
49. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011;6:e28691.
50. Wong EB, Omar T, Sedhako G, et al. Causes of death in ART-treated adults: a post-mortem study from Johannesburg. XVIII International AIDS Conference; Vienna, Austria, 2010.